Article

Incretin-based therapies in type 2 diabetes: a review of clinical results.

Department of Internal Medicine, Diabetes and Endocrinology Unit, San Raffaele Scientific Institute and San Raffaele Vita Salute University, Via Olgettina 60, 20132 Milano, Italy.
Diabetes research and clinical practice (Impact Factor: 2.54). 12/2008; 82 Suppl 2:S102-7. DOI: 10.1016/j.diabres.2008.10.003
Source: PubMed

ABSTRACT GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 diabetes. The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial glucose. Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome. The low rate of hypoglycemic events seen in all studies confirms the glucose dependent action of incretins.

Full-text

Available from: Emanuele Bosi, Sep 27, 2014
0 Followers
 · 
129 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence of type 2 diabetes in the UK has increased enormously over recent years and is closely associated with obesity and other risk factors for cardiovascular disease. The incretin system, which contributes significantly to the insulin response in healthy individuals, but is impaired in individuals with diabetes, offers a target for the development of agents that address many aspects of diabetes. These agents are broadly split into two categories — the glucagon-like polypeptide-1 (GLP-1) receptor agonists and the dipeptidyl peptidase-4 (DPP-4) inhibitors. The DPP-4 inhibitors sitagliptin and vildagliptin, along with the GLP-1 receptor agonists exenatide and liraglutide are currently approved for use and offer effective glycaemic control with a low risk of hypoglycaemia. GLP-1 receptor agonists may offer further benefits over both DPP-4 inhibitors and conventional therapies, such as reductions in body weight and blood pressure. Here we review the incretin system (with particular reference to GLP-1) and consider the development of these two classes of antidiabetic therapy, discussing the safety and efficacy of some of the latest available GLP-1 receptor agonists and DPP-4 inhibitors.
    The British Journal of Diabetes & Vascular Disease 02/2010; 10(1):21-30. DOI:10.1177/1474651409357266
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study evaluates the relationship between HbA1c and weight change outcomes by anti-diabetic weight-effect properties in patients newly treated for type 2 diabetes; a relationship not previously characterized. Electronic medical records of patients with type 2 diabetes newly prescribed anti-diabetic monotherapy were assessed to identify HbA1c goal attainment [(<53mmol/mol)] and weight change at 1-year. Anti-diabetics were categorized by weight-effect properties: weight-gain (sulfonylureas, thiazolidinediones) and weight-loss/neutral (metformin, DPP-4 inhibitors, GLP-1 agonists). Logistic regression analyses identified likelihood of attaining HbA1c goal or ≥3% weight loss by anti-diabetic category controlling for baseline characteristics. MANOVA was used to identify correlation between changes in weight and HbA1c. The study included 28,290 patients. Mean age±sd was 61 years ±11.8. Baseline HbA1c was 7.4%±1.6 (57mmol/mol±17); 67.3% were prescribed a weight-loss/neutral anti-diabetic. At 1-year, more patients in the weight-loss/neutral anti-diabetic category lost weight (≥3%) than in the weight-gain anti-diabetic category (40.4% vs. 24.2%, p<0.001) or had an HbA1c<7.0% (<53mmol/mol) (71.1% vs. 63.8%, p<0.001). Those prescribed a weight-gain anti-diabetic were 53% less likely to lose weight and 29% less likely to be at HbA1c goal than those prescribed a weight-loss/neutral anti-diabetic (p<0.001). Weight loss and HbA1c outcomes were significantly correlated (p<0.001). Weight loss of ≥3% was associated with better glycemic control in patients newly treated for type 2 diabetes. Anti-diabetics associated with weight-loss/neutrality were associated with greater weight loss and HbA1c goal attainment and may facilitate efforts to co-manage weight and glycemia in the ambulatory-care setting.
    Diabetes research and clinical practice 01/2014; 103(3). DOI:10.1016/j.diabres.2013.12.038 · 2.54 Impact Factor
  • Chemical Reviews 02/2013; 113(5). DOI:10.1021/cr100264t · 45.66 Impact Factor